BioStock: CombiGene comments on their latest progress
Last week, CombiGene reported that the company’s two warrants were exercised at 98.4 percent, which thus added just over SEK 25 million to the company. In addition, one of the company’s co-founders, Associate Professor David Woldbye, published a peer-reviewed article in Frontiers in Molecular Neuroscience, concerning CombiGene’s epilepsy project CG01. BioStock reached out to CEO Jan Nilsson for a comment.Read the full interview with CombiGene's CEO Jan Nilsson at biostock.se: https://www.biostock.se/en/combigene-comments-on-their-latest-progress/This is a pressrelease from BioStock -